GSK Targets Oncology Dominance with $10.6 Billion Nuvalent Buyout

Valuing shares at a 40% premium, GSK has launched a $10.6 billion bid for Nuvalent, signaling an aggressive pivot toward specialized cancer therapies. This all-cash deal represents the largest strategic maneuver under CEO Luke Miels to replenish the company's drug pipeline before critical HIV treatment patents expire in 2028.

Editorial·June 9, 2026·reads: 2,423

GSK Targets Oncology Dominance with $10.6 Billion Nuvalent Buyout

The acquisition of Nuvalent, priced at roughly $124 per share, marks a departure from GSK’s historical preference for smaller, incremental deals. By securing the Massachusetts-based developer, GSK intends to close the competitive gap with AstraZeneca, which currently derives 44% of its revenue from oncology. For GSK, the move is essential to reaching its target of £40 billion in annual revenue by 2031.

Beyond the financials, the merger aims to bolster the company’s lung cancer portfolio with new, specialized treatment options. With the transaction expected to close by the third quarter of 2026, the net cost to GSK will stand at approximately $9.4 billion once cash holdings are accounted for. This push underscores a broader industry race to dominate the oncology market as legacy blockbuster drugs face looming generic competition.